論文 - 詳細
| RRC ID | 11912 |
|---|---|
| 著者 | Kato M, Hagiwara Y, Oda T, Imamura-Takai M, Aono H, Nakamura M. |
| タイトル | Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. |
| ジャーナル | J Ocul Pharmacol Ther |
| Abstract |
PURPOSE:Glucocorticoids exert their actions via the glucocorticoid receptor through at least 2 intracellular mechanisms, known as transrepression and transactivation. It has been hypothesized that transrepression is the basis of their anti-inflammatory effects, whereas transactivation has been assumed to cause their side effects. ZK209614, a recently identified, novel selective glucocorticoid receptor agonist, exerts strong transrepression and weak transactivation. The objective of this study was to determine whether its pharmacological effects can be dissociated from its side effects. For this, we employed in vitro assays and topical in vivo models. METHODS:ZK209614 and dexamethasone were used in in vitro transrepression and transactivation assays. To evaluate anti-inflammatory and antiallergic activities in vivo, ZK209614 and betamethasone phosphate were tested in the carrageenan-induced conjunctivitis model and allergic conjunctivitis model in rats. To evaluate side effects in vivo, treatments with ZK209614 and betamethasone phosphate were tested for the ocular hypertensive effects in a feline model, each drug being administered topically. RESULTS:ZK209614 showed strong transrepression and weak transactivation in the in vitro assays. When given as eyedrops, ZK209614 and betamethasone phosphate each had an inhibitory effect on edema weight in the rat carrageenan-induced conjunctivitis model. In the rat allergic conjunctivitis model, ZK209614 reduced the elevated vascular permeability at a concentration of 0.1%. In the feline intraocular pressure (IOP)-elevation experiment, topically administered betamethasone phosphate elevated IOP, but ZK209614 had no effect on IOP. CONCLUSION:The present investigations suggest that ZK209614 eyedrops have both anti-inflammatory and antiallergic effects, but no unwanted IOP-elevating effect. On that basis, ZK209614 might be a promising candidate as an ophthalmic drug with a better therapeutic index than classic glucocorticoids. |
| 巻・号 | 27(4) |
| ページ | 353-60 |
| 公開日 | 2011-8-1 |
| DOI | 10.1089/jop.2010.0177 |
| PMID | 21574866 |
| MeSH | Administration, Topical Animals Anti-Inflammatory Agents / administration & dosage Anti-Inflammatory Agents / pharmacology* Anti-Inflammatory Agents / toxicity Benzofurans / administration & dosage Benzofurans / pharmacology* Benzofurans / toxicity Benzoxazines / administration & dosage Benzoxazines / pharmacology* Benzoxazines / toxicity Betamethasone / administration & dosage Betamethasone / analogs & derivatives Betamethasone / pharmacology Betamethasone / toxicity Carrageenan Cats Cell Line, Tumor Cells, Cultured Conjunctivitis / drug therapy* Conjunctivitis, Allergic / drug therapy Dexamethasone / administration & dosage Dexamethasone / pharmacology Dexamethasone / toxicity Disease Models, Animal Glucocorticoids / administration & dosage Glucocorticoids / pharmacology* Glucocorticoids / toxicity Humans Intraocular Pressure / drug effects Male Ophthalmic Solutions Rats Rats, Inbred BN Rats, Wistar Receptors, Glucocorticoid / agonists* Toxicity Tests Transcriptional Activation / drug effects |
| IF | 1.961 |
| 引用数 | 14 |
| WOS 分野 | OPHTHALMOLOGY PHARMACOLOGY & PHARMACY |
| リソース情報 | |
| ヒト・動物細胞 | HCE-T(RCB2280) |